NCT07473700招募中2 期
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Tectonic Operating Company, Inc.22 个研究点 分布在 6 个国家目标入组 25 人开始时间: 2026年10月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 22
- 主要终点
- Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in association with connective tissue disease, occupational ILD, or chronic hypersensitivity pneumonitis. Chest CTs will be centrally read for eligibility
- •40% predicted less than or equal to (<=) forced vital capacity (FVC) <= 80% predicted at screening
- •At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18 months of screening with mean pulmonary arterial pressure (mPAP) >= 25 millimeters of mercury (mm Hg), pulmonary capillary wedge pressure (PCWP) <=15 mm Hg, and pulmonary vascular resistance (PVR) >=4 Wood units; Documented echocardiogram (ECHO) within 18 months of screening with right ventricular (RV) (or pulmonary artery) systolic pressure >46 mm Hg or tricuspid annular plane systolic excursion (TAPSE)/ systolic pulmonary artery pressure (SPAP) <=0.38 and absence of clinically significant left ventricular dysfunction as assessed by the investigator
排除标准
- •Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4, or WHO Group 5
- •Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous (IV) or subcutaneous (SC) prostacyclin analogues within 30 days before the first screening visit, or sotatercept within 180 days before the first screening visit
- •Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol
- •Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and anti-inflammatory medications) who are not on stable doses for >30 days before the first screening visit or have initiated new ILD-directed therapies within 90 days before the first screening visit
研究组 & 干预措施
TX000045 300 mg
Experimental
Participants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13.
干预措施: TX000045 (Drug)
结局指标
主要结局
Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
时间窗: Baseline up to 21 weeks
Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Assessments, 12-Lead Electrocardiogram (ECG) Assessments and Vital Sign Assessments
时间窗: Baseline up to 21 weeks
Mean Change from Baseline in PVR up to 16 Weeks
时间窗: Baseline up to 16 weeks
次要结局
- Mean Change from Baseline in Mean Pulmonary Arterial Pressure (mPAP) up to 21 Weeks(Baseline up to 21 weeks)
- Mean Change from Baseline in Hemodynamic Parameter: Pulmonary Capillary Wedge Pressure (PCWP)(Baseline up to 21 weeks)
- Mean Change from Baseline in Hemodynamic Parameter: Cardiac Output (CO)(Baseline up to 21 weeks)
- Mean Change from Baseline in Hemodynamic Parameter: Stroke Volume (SV)(Baseline up to 21 weeks)
- Mean Change from Baseline in Resting Arterial Oxygen Saturation (SpO2) up to 21 Weeks(Baseline up to 21 weeks)
- Mean Change from Baseline in Supplemental Oxygen Requirement (L/min) up to 21 Weeks(Baseline up to 21 weeks)
- Mean Change from Baseline in the Nadir of the SpO2 During the 6-minute walk test (6MWT) up to 21 Weeks(Baseline up to 21 weeks)
- Mean Change from Baseline in Oxygen Saturation (SpO2)at 1, 2, and 3 Minutes after Completion of the 6-MWT up to 21 Weeks(Baseline up to 21 weeks)
- Mean Change from Baseline in Distance Walked During the 6MWT at Which an Absolute Decrease of SpO2>4% for At least 15 Second(Baseline up to 21 weeks)
研究者
研究点 (22)
Loading locations...
相似试验
招募中
不适用
Single-step vs Stepwise Lung Recruitment Maneuvers After Cardiopulmonary BypassNCT07432477Ondokuz Mayıs University52
招募中
4 期
A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and functional status in pulmonary hypertension (IRON-PH)Pulmonary hypertension2025-522936-14-00Ziekenhuis Oost Limburg306
招募中
4 期
LEVOMEMS: Comparison of the effects of dobutamine and levosimendan in the current treatment of heart diseases.2024-519631-42-00Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol10
招募中
2 期
A Phase 2 Study of PTX-100 Monotherapy in Patients with r/r CTCL2025-521852-45-00Prescient Therapeutics Limited25
尚未招募
不适用
Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)NCT07263958University of Sao Paulo General Hospital15